A Study Of Different Doses Of UK-453, 061 Plus Truvada Compared To Efavirenz Plus Truvada In Patients Who Have Not Been Previously Treated For HIV-1

NCT00824421

Last updated date
Study Location
Pfizer Investigational Site
Buenos Aires, , C1405BCH, Argentina
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
HIV-1
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Male or female at least 18 years of age available for a follow-up period of at least 96 weeks.

- HIV 1 RNA viral load of greater then 1,000 copies/mL

- Negative urine pregnancy test.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Suspected or documented active, untreated HIV-1 related opportunist infection or other
condition requiring acute therapy at the time of randomization.


- Subjects with acute Hepatitis B and/or C within 30 days of randomization.


- Absolute CD4 count <200 cells/mm3.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

HIV-1A Long Term Safety Study Of Lersivirine For The Treatment Of HIV-1 Infection In Subjects Who Have Completed Treatment With Lersivirine In Studies A5271015 And A5271022
NCT01254656
  1. Darlinghurst, New South Wales
  2. Melbourne, Victoria
  3. Nova Iguacu, RJ
  4. Toronto, Ontario
  5. Montreal, Quebec
  6. Montreal, Quebec
  7. Milano,
  8. Torino,
  9. Mexico, Distrito Federal
  10. Bydgoszcz,
  11. Warszawa,
  12. Johannesburg, Gauteng
  13. Pretoria, Gauteng
  14. Soweto, Gauteng
  15. Durban, Kwazulu-Natal
  16. Cape Town, Western Cape
  17. Pretoria,
  18. Lugano,
  19. St. Gallen,
  20. Zuerich,
  21. Brighton, East Sussex
  22. London,
  23. London,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
HIV-1A Rollover Study For Subjects Discontinuing From UK-453,061 Studies For The Treatment Of HIV-1
NCT00824369
  1. Sacramento, California
  2. Sacramento, California
  3. Miami, Florida
  4. Atlanta, Georgia
  5. Cincinnati, Ohio
  6. Dallas, Texas
  7. Buenos Aires,
  8. Curitiba, PR
  9. Nova Iguacu, RJ
  10. Campinas, SP
  11. Sao Paulo, SP
  12. Milano,
  13. Kota Bharu, Kelantan
  14. Warszawa,
  15. Lisboa,
  16. Porto,
  17. Ponce,
  18. Santurce,
  19. Dundee, Kwazulu-Natal
  20. Cape Town, Western Cape
  21. Lugano,
  22. St. Gallen,
  23. Donetsk,
  24. Edinburgh,
  25. Edinburgh,
  26. London,
  27. Manchester,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
HIV-1A Phase 2B Multicenter, Randomized, Comparative Trial Of UK-453,061 Versus Etravirine In Combination With Darunavir/Ritonavir And A Nucleos(t)Ide Reverse Transcriptase Inhibitor For The Treatment Of Antiretroviral Experienced HIV-1 Infected Subjects With Evidence Of NNRTI Resistant HIV-1
NCT00823979
  1. Los Angeles, California
  2. Los Angeles, California
  3. Sacramento, California
  4. Sacramento, California
  5. San Francisco, California
  6. Miami, Florida
  7. Miami, Florida
  8. Orlando, Florida
  9. Pensacola, Florida
  10. Tampa, Florida
  11. Atlanta, Georgia
  12. Chicago, Illinois
  13. East Meadow, New York
  14. Mount Vernon, New York
  15. Huntersville, North Carolina
  16. Cincinnati, Ohio
  17. Bellaire, Texas
  18. Conroe, Texas
  19. Dallas, Texas
  20. Dallas, Texas
  21. Stafford, Texas
  22. Curitiba, PR
  23. Nova Iguacu, RJ
  24. PoA, RS
  25. Campinas, SP
  26. Sao Paulo, SP
  27. Sao Paulo, SP
  28. Koeln,
  29. Bologna,
  30. Roma,
  31. Kota Bharu, Kelantan
  32. Kuala Lumpur,
  33. Szczecin,
  34. Warszawa,
  35. Coimbra,
  36. Lisboa,
  37. Lisboa,
  38. Porto,
  39. Porto,
  40. Bayamon,
  41. Ponce,
  42. Rio Piedras,
  43. San Juan,
  44. San Juan,
  45. Johannesburg, Gauteng
  46. Johannesburg, Gauteng
  47. Soweto, Johannesburg
  48. Dundee, Kwazulu-natal
  49. Durban, Kwazulu-natal
  50. Cape Town, Western CAPE
  51. Cape Town, Western CAPE
  52. Badalona, Barcelona
  53. Madrid,
  54. Kaohsiung County,
  55. Taipei,
  56. Berezyna, Vinnitsa District, Vinnitsa Region
  57. Donetsk,
  58. Lugansk,
  59. Brighton, EAST Sussex
  60. Crumpsall, Greater Manchester
  61. Edinburgh,
  62. Edinburgh,
  63. London,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A Study Of Different Doses Of UK-453, 061 Plus Truvada Compared To Efavirenz Plus Truvada In Patients Who Have Not Been Previously Treated For HIV-1
Official Title  ICMJE A Phase 2B Multicenter, Randomized, Double-Blind, Comparative Trial Of UK-453,061, In Combination With Tenofovir Df And Emtricitabine Versus Efavirenz In Combination With Tenofovir DF And Emtricitabine For The Treatment Of Antiretroviral-Naive HIV-1 Infected Subjects
Brief Summary This is a 96 week study to determine if UK- 453,061 in combination with Truvada is as efficacious, safe and tolerable as efavirenz in combination with Truvada in HIV-1 infected patients who have not been previously treated with antiretroviral drugs.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Condition  ICMJE HIV-1
Intervention  ICMJE
  • Drug: UK-453, 061
    UK-453,061 500 mg tablets PO QD + Tenofovir DF 300 mg/Emtricitabine 200 mg tablets PO QD.
  • Drug: UK-453, 061
    UK-453,061 750 mg tablets PO QD + Tenofovir DF 300 mg/Emtricitabine 200 mg tablets PO QD.
  • Drug: EFV +TVA
    Efavirenz 600 mg tablets PO QD + Tenofovir DF 300 mg/Emtricitabine 200 tablets mg PO QD.
Study Arms  ICMJE
  • Experimental: UK- 453,061 Dose One
    UK 453,061 Dose One plus Truvada
    Intervention: Drug: UK-453, 061
  • Experimental: UK-453,061 Dose Two
    UK 453,061 Dose Two plus Truvada
    Intervention: Drug: UK-453, 061
  • Active Comparator: Efavirenz + Truvada
    Efavirenz + Truvada
    Intervention: Drug: EFV +TVA
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: November 23, 2011)
195
Original Estimated Enrollment  ICMJE
 (submitted: January 15, 2009)
189
Actual Study Completion Date  ICMJE October 2011
Actual Primary Completion Date October 2011   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Male or female at least 18 years of age available for a follow-up period of at least 96 weeks.
  • HIV 1 RNA viral load of greater then 1,000 copies/mL
  • Negative urine pregnancy test.

Exclusion Criteria:

  • Suspected or documented active, untreated HIV-1 related opportunist infection or other condition requiring acute therapy at the time of randomization.
  • Subjects with acute Hepatitis B and/or C within 30 days of randomization.
  • Absolute CD4 count <200 cells/mm3.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Argentina,   Australia,   Canada,   Italy,   Mexico,   Poland,   South Africa,   Switzerland,   United Kingdom
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00824421
Other Study ID Numbers  ICMJE A5271015
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date November 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP